Johnson & Johnson says COVID-19 vaccine 85 per cent effective against severe illness
OTTAWA -- American pharmaceutical giant Johnson and Johnson says its vaccine is very good at preventing people from being hospitalized or dying from COVID-19.
The vaccine is the first to use just a single dose and can be stored in a fridge for up to three months, making it a potential game changer in the COVID-19 vaccination campaign.
The results aren't quite as good as those seen in the two vaccines Health Canada has already approved, with both Pfizer-BioNTech and Moderna saying their vaccines showed 95 per cent efficacy against severe illness.
Johnson and Johnson says it's single-dose vaccine is 85 per cent effective against severe illness a month after the injection is given, and 66 per cent effective against both moderate and severe illness.
The federal government has already pre-purchased 10 million doses of the vaccine, but it is still being reviewed by Health Canada.
There is no timeline yet for when approval might come or when those doses would be delivered for use in Canada.
- What you need to know about Johnson & Johnson’s approved single-dose vaccine
- Health Canada to announce approval of Johnson and Johnson vaccine against COVID-19
- Canada to get 1.9M vaccine doses this week, including first Johnson & Johnson shots
- Canada to get two million Pfizer-BioNTech vaccine doses as provinces expand rollouts
- Health Canada approves AstraZeneca’s COVID-19 vaccine
- BRAMPTON'S MOST WANTED: Peel Police hunt four men on the run
- VIDEO: All lanes blocked on Hwy 401 due to multiple vehicles pile up in Mississauga
- Another 7 flights with 38 rows affected land with COVID-19 at Pearson Airport in Mississauga
- Mississauga, Brampton to lift restrictions once Ontario's COVID numbers are "well below" 1,000 daily cases
- Peel orders closure of eight businesses including a bank and hotel in Mississauga and Brampton